<h4>Background</h4>Prostate-specific antigen velocity (PSAV) has emerged as a promising biomarker for predicting survival outcomes in prostate cancer patients.<h4>Objectives</h4>To assess the association between PSAV and both all-cause mortality and prostate cancer-specific mortality (PCSM) in men diagnosed with prostate cancer by conducting a meta-analysis.<h4>Methods</h4>A comprehensive search of electronic medical databases, including PubMed, Web of Science, and Embase, was conducted to identify relevant studies published up to March 1, 2025. This evidence concerns the gene KLK3 and prostate cancer.